Resource Library
Showing 181 to 190 of 327 results
Dr. Rena Buckstein from Odette Cancer Centre in Toronto shares the basics of myelodysplastic syndromes (MDS) diagnosis, treatment, and side effects.
Graft vs Host Disease, known as GvHD, is a side effect of a life saving procedure. People who undergo an allogeneic stem cell transplant - when a donor's stem cells are transplanted into the recipient - can experience either acute or chronic GvHD. In this podcast, listen to blood cancer survivor Libby Goszer, who describes her experience living with…
In this presentation, Dr. John Dick, one of Canada’s pioneering scientists in the field of “cancer stem cells”, will explain how his research into the causes of blood cancers holds the promise for improved treatments and quality of life for Canadians affected by blood cancers.
In this 2025 webcast, four scientists funded by the LLSC's AI Catalyst Grant talk about their work investigating how AI / machine learning can speed up discovery and detection of blood cancers in their research work. Moderated by Dr. Paul O'Connell, LLSC Research Program Director.
Multiple myeloma, or MM, is a type of blood cancer that starts in the bone marrow. Multiple myeloma affects plasma cells, a type of white blood cell that normally fights infection, turning healthy cells into cancer cells that can damage blood, bones and kidneys.
Immune effector cell-associated neurotoxicity syndrome (ICANS) is a side effect that can happen after some forms of immunotherapy treatment. It may cause you to experience serious neurological symptoms.
In this 1-hour live webcast, Dr. Sonia Cerquozzi, hematologist at the Tom Baker Cancer Center and Peter Lougheed Centre in Calgary, reviews PV, a type of MPN - its diagnosis, treatment options and aspects of follow-up care.
Diffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL). DLBCL is fast-growing (aggressive) but treatable. It most often appears in older adults but can appear at any age.
Cutaneous T-cell lymphoma (CTCL) is a slow-growing (indolent) subtype of non-Hodgkin lymphoma (NHL). CTCL is rare, representing 4% of NHL cases. It starts in white blood cells (lymphocytes) that reside in the skin, called T-cells.
Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin lymphoma. It is a blood cancer of the B-lymphocytes (type of white blood cell that fights infections) found in the bone marrow. Learn more about MCL in this animated video.